Profitelligence Profitelligence · Filing Ledger Open DHR research →

Form 8-K · Current Report · Filed 2026-01-27

Danaher Reports 2025 Financial Results and Provides 2026 Guidance

Danaher Corporation announced its 2025 financial results, reporting net earnings of $3.6 billion, or $5.03 per diluted share.

Filer
Danaher Corporation DHR · NYSE
Filed
Accession
0000313616-26-000004
CIK
0000313616
Signal
High impactHealthcare

Details

The company saw revenue increase by 3% to $24.6 billion, with non-GAAP core revenue rising by 2%. Operating cash flow was $6.4 billion, and free cash flow was $5.3 billion. For 2026, Danaher anticipates non-GAAP core revenue growth in the range of 3% to 6% and adjusted diluted net earnings per share between $8.35 and $8.50. The company also adjusted its financial measures to exclude certain items to better reflect underlying performance.

Items reported

Item events

Reported Item

General Statement Earnings Beat Raised Guidance

Market reaction

Close before filing

$236.71

Next session

-5.1%

Since filing

-17.6%

Latest close

$194.98

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from DHR reporting the same item, with the next session's move:

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another DHR filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts